Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study [1] (multiple letters)

Lancet

Volumn 359, Issue 9324, 2002, Pages 2199-2204

  Poole Wilson, Philip A ^a   Lubsen, Jacobus ^b,c   Wiedermann, Christian J ^d   Hamon, Martial ^e   Cruickshank, John Malcolm ^f   Bloom, Jeffrey M ^g   Bursztyn, Michael ^h   Hjelmesaeth, Jøran ⁱ   Carlsson, Per Ola ^j,k   Cockcroft, J R ^l   Brown, M J ^m   Montastruc, J L ⁿ   Pathak, A ⁿ   Lapeyre Mestre, M ⁿ   Fuchs, Flávio Danni ^o   Dahlöf, Björn ^p   Lindholm, Lars H ^q  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SOCAR RESEARCH SA   (Switzerland)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f Oxonian Cardiovascular Consultancy   (United Kingdom)

^g Central Coast Primary Care   (United States)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j Vestfold Central Hospital   (Norway)

^k UPPSALA UNIVERSITY   (Sweden)

^l CARDIFF UNIVERSITY   (United Kingdom)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ Service de Pharmacologie Clinique   (France)

^o HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^p SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^q UMEÅ UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DOXAZOSIN; LISINOPRIL; LOSARTAN; METOPROLOL; OXPRENOLOL; PROPRANOLOL; ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; LETTER; MORBIDITY; PRIORITY JOURNAL; STROKE; SURVIVAL; DRUG EFFECT; HEART RATE; MORTALITY; NOTE; RISK FACTOR; DRUG COMBINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; BIOASSAY; PUBLICATION; REPRODUCIBILITY; STANDARD;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; LOSARTAN; RISK FACTORS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; PERIODICALS; REPRODUCIBILITY OF RESULTS;

EID: 0037157749     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09068-2     Document Type: Letter

References (0)